|
1B56
HUMAN RECOMBINANT EPIDERMAL FATTY ACID BINDING PROTEIN
提交 1999-01-12
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
PLM PALMITIC ACID × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
pH 6;pH 6.0
|
分辨率 2.05 Å
R-free 0.260
|
|
1JJJ
SOLUTION STRUCTURE OF RECOMBINANT HUMAN EPIDERMAL-TYPE FATTY ACID BINDING PROTEIN
提交 2001-07-06
|
配体/离子不同
实验方法不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
未记录非水小分子
|
SOLUTION NMR
NMR测量条件
pH 5.6;298 K;离子强度(mmCIF原始值)20 mM POTASSIUM PHOSPHATE;压力 AMBIENT
NMR样品组成
1.5-2 MM E-FABP PHOSPHATE BUFFER; 0.05% SODIUM AZIDE
|
分辨率未提供
|
|
4AZM
Human epidermal fatty acid-binding protein (FABP5) in complex with the inhibitor BMS-309413
提交 2012-06-26
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
1–135(135 aa)
链 B
1–135(135 aa)
|
未记录
|
T4B ((2'-(5-ETHYL-3,4-DIPHENYL-1H-PYRAZOL-1-YL)-3-BIPHENYLYL)OXY)ACETIC ACID × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.32 M SODIUM CITRATE, 0.1 M HEPES PH 7.0, SATURATED WITH RESPECT TO BMS-309403, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K. CRYOPROTECTION: 28% GLYCEROL IN MOTHER LIQUOR.
|
分辨率 2.75 Å
R-free 0.252
|
|
4AZR
Human epidermal fatty acid-binding protein (FABP5) in complex with the endocannabinoid anandamide
提交 2012-06-26
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
1–135(135 aa)
链 B
1–135(135 aa)
|
未记录
|
A9M N-(2-hydroxyethyl)icosanamide × 2
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
pH 7.5;25% PEG 3350, 0.1 M HEPES PH 7.5. FABP INCUBATED IN A SOLUTION SATURATED WITH RESPECT TO ANANDAMIDE PRIOR TO CRYSTALLIZATION. CRYPROTECTION: 25% GLYCEROL IN MOTHER LIQUOR.
|
分辨率 2.95 Å
R-free 0.268
|
|
4LKP
Crystal Structure of Apo Human Epidermal Fatty Acid Binding Protein (FABP5)
提交 2013-07-08
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
CL CHLORIDE ION × 1
DMS DIMETHYL SULFOXIDE × 2
NH4 AMMONIUM ION × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 5.6;291 K;2.0M ammonium sulfate, 300mM Na/K tartrate, 100mM Na citrate, pH 5.6, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
分辨率 1.67 Å
R-free 0.214
|
|
5HZ5
FABP5 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline
提交 2016-02-02
|
构建体不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
2–135(134 aa)
片段:SOLUBLE FORM, RESIDUES 2-135
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 1
65X 6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;295 K
|
分辨率 1.40 Å
R-free 0.228
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 3
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 B
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 2
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 3
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 C
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 2
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 4
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 D
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 2
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 5
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 E
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 6
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 F
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 7
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 G
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 2
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
5UR9
Enantiomer-Specific Binding of the Potent Antinociceptive Agent SBFI-26 to Anandamide transporters FABP5
提交 2017-02-09
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 8
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 H
1–135(135 aa)
|
未记录
|
8KS (1S,2S,3S,4S)-3-{[(naphthalen-1-yl)oxy]carbonyl}-2,4-diphenylcyclobutane-1-carboxylic acid × 1
SO4 SULFATE ION × 1
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;0.1 M HEPES, pH 7.5, 2% polyethylene glycol 400, and 2.1 M ammonium sulfate 15
|
分辨率 2.20 Å
R-free 0.237
|
|
7FWI
Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
NC0 2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.00 Å
R-free 0.273
|
|
7FWI
Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 B
1–135(135 aa)
|
未记录
|
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.00 Å
R-free 0.273
|
|
7FWI
Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 3
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 C
1–135(135 aa)
|
未记录
|
NC0 2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.00 Å
R-free 0.273
|
|
7FXD
Crystal Structure of human FABP5 in complex with 2-(indole-1-carbonylamino)benzoic acid, i.e. SMILES c12N(C(=O)Nc3c(cccc3)C(=O)O)C=Cc1cccc2 with IC50=18.1696 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
NC0 2-[(2,3-dihydro-1H-indole-1-carbonyl)amino]benzoic acid × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 2.44 Å
R-free 0.280
|
|
7FY0
Crystal Structure of human FABP5 in complex with (2R)-1-[(3,5-dichloro-2-phenylphenyl)carbamoyl]pyrrolidine-2-carboxylic acid, i.e. SMILES c1(cc(cc(c1c1ccccc1)Cl)Cl)NC(=O)N1CCC[C@@H]1C(=O)O with IC50=18 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 3
UOF 1-[(4,6-dichloro[1,1'-biphenyl]-2-yl)carbamoyl]-D-proline × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.34 Å
R-free 0.192
|
|
7FYD
Crystal Structure of human FABP5 in complex with 6-chloro-4-phenyl-2-propan-2-ylquinoline-3-carboxylic acid, i.e. SMILES c1(ccc2c(c1)c(c1ccccc1)c(c(n2)C(C)C)C(=O)O)Cl with IC50=2.6 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 2
VLQ 6-chloro-4-phenyl-2-(propan-2-yl)quinoline-3-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.45 Å
R-free 0.223
|
|
7G01
Crystal Structure of human FABP5 in complex with 6-chloro-4-phenyl-2-piperidin-1-ylquinoline-3-carboxylic acid, i.e. SMILES n1c(c(c(c2c1ccc(c2)Cl)c1ccccc1)C(=O)O)N1CCCCC1 with IC50=1.1 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 1
5M7 6-chloranyl-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid × 2
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.17 Å
R-free 0.171
|
|
7G04
Crystal Structure of human FABP5 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid, i.e. SMILES c12c(ccc(c2)c2ccc(cc2)Cl)CCC[C@H]1C(=O)O with IC50=3.3 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
未记录非水小分子
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.40 Å
R-free 0.220
|
|
7G04
Crystal Structure of human FABP5 in complex with 7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid, i.e. SMILES c12c(ccc(c2)c2ccc(cc2)Cl)CCC[C@H]1C(=O)O with IC50=3.3 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 B
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 1
CL CHLORIDE ION × 1
WXZ (1R)-7-(4-chlorophenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.40 Å
R-free 0.220
|
|
7G0B
Crystal Structure of human FABP5 in complex with 7-bromo-1-methyl-5-phenyl-2,3,4,5-tetrahydro-1-benzazepine-4-carboxylic acid, i.e. SMILES [C@@H]1([C@@H](CCN(c2c1cc(cc2)Br)C)C(=O)O)c1ccccc1 with IC50=2.3 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 1
WK0 (4S,5S)-7-bromo-1-methyl-5-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.47 Å
R-free 0.219
|
|
7G0E
Crystal Structure of human FABP5 in complex with 2-[(3-ethoxycarbonyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)carbamoyl]cyclopentene-1-carboxylic acid, i.e. SMILES C1CCC2=C(C1)C(=C(S2)NC(=O)C1=C(C(=O)O)CCC1)C(=O)OCC with IC50=1.1 microM
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
L8T 2-{[3-(ethoxycarbonyl)-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]carbamoyl}cyclopent-1-ene-1-carboxylic acid × 2
SO4 SULFATE ION × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.11 Å
R-free 0.191
|
|
7G1Q
Crystal Structure of human FABP5 in complex with (1S,2R)-2-[(5-carbamoyl-3-ethoxycarbonyl-4-methyl-2-thienyl)carbamoyl]cyclohexanecarboxylic acid
提交 2023-04-27
|
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白单体
单体;蛋白 × 1
PDB 声明:monomeric
|
链 A
1–135(135 aa)
|
未记录
|
DMS DIMETHYL SULFOXIDE × 1
SO4 SULFATE ION × 2
IOV (1R,2S)-2-{[5-carbamoyl-3-(ethoxycarbonyl)-4-methylthiophen-2-yl]carbamoyl}cyclohexane-1-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;protein in 25mM Tris/HCl pH 7.5 100mM NaCl, see also PMID 27658368
|
分辨率 1.24 Å
R-free 0.201
|